Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case- control study from Denmark  Sidsel Arnspang Pedersen, MD, David Gaist,

Similar presentations


Presentation on theme: "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case- control study from Denmark  Sidsel Arnspang Pedersen, MD, David Gaist,"— Presentation transcript:

1 Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case- control study from Denmark  Sidsel Arnspang Pedersen, MD, David Gaist, PhD, Sigrun Alba Johannesdottir Schmidt, PhD, Lisbet Rosenkrantz Hölmich, DMSc, Søren Friis, MD, Anton Pottegård, PhD  Journal of the American Academy of Dermatology  Volume 78, Issue 4, Pages e9 (April 2018) DOI: /j.jaad Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Flowchart of case selection. ∗Azathioprine, cyclosporine, and mycophenolate mofetil. BCC, Basal cell carcinoma; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Dose-response pattern between cumulative hydrochlorothiazide dose and risk of basal cell carcinoma (A) and squamous cell carcinoma (B). Error bars represent 95% confidence intervals. Journal of the American Academy of Dermatology  , e9DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions


Download ppt "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case- control study from Denmark  Sidsel Arnspang Pedersen, MD, David Gaist,"

Similar presentations


Ads by Google